RVMD News

Key Factors

Recent Updates

Catalyst

Recent Bullish Engulfing and MACD Golden Cross signals on February 19 and 23, 2026, indicate strong bullish momentum for RVMD.

Risk

Market expectations for RVMD tend to be pessimistic, with analyst ratings showing differences rather than consensus.
Fund flow analysis shows a negative overall trend with large and extra-large investor inflow ratios below 50%.

Generated at22:5403/31/2026by

Aime

Newswire

14:02

Revolution Medicines MACD Death Cross & Narrowing Bollinger Bands on 15min chart.

19:23

Revolution Medicines, Inc. (RVMD): A Promising Precision Oncology Company

20:07

Revolution Medicines' Mancini Sells Shares, Buys Others at Lower Price

12:17

Revolution Medicines's 15min chart shows KDJ Death Cross, Bearish Marubozu signal.

14:33

Revolution Medicines' stock price hits Bollinger Bands Narrowing with Bearish Marubozu signal.

About RVMD

Charts

SectorBiological Technology

Established Date--

Listing Date13/02/2020

ExchangeNASDAQ Stock Exchange

Full-time Employees883

Fiscal Year Ends31/12

Websitewww.revmed.com;ir.revmed.com

Security TypeCommon stock

Office address700 Saginaw Drive, Redwood City, CA 94063

Business

Introduction

Revolution Medicines, Inc., founded in October 2014, is a Delaware corporation. The company is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit cutting-edge targets in RAS addictive cancer. The company has advanced structure-based drug discovery capabilities based on deep knowledge of chemical biology and cancer pharmacology and innovative proprietary technologies to create small molecules suitable for unconventional binding sites. The company's understanding of cancer's genetic drivers and adaptive resistance mechanisms, coupled with strong drug discovery and pharmacochemistry capabilities, has guided the establishment of a deep pipeline for key signaling nodes in the RAS pathway and related pathways.